Five hundred and eighty million euros of investment over the next five years, of which 125 million will be earmarked to support the production capacity of the Latina plant. Significant numbers announced by Johnson & Johnson Innovative Medicine yesterday morning during the “Together towards the medicine of the future” event at the Borgo San Michele plant.
The Minister of Business and Made in Italy, Adolfo Urso, and the President of the Lazio Region Francesco Rocca had arrived for the occasion. During the meeting, the company reaffirmed its commitment to Italy, aiming to improve the attractiveness and competitiveness of the territory, as well as to support excellent pharmaceutical research and production. Jorge Lopez, general manager of the Latina plant, said: «The Latina plant is experiencing a significant evolution, we are strengthening our capabilities to serve a greater number of patients with innovative products. The investment plan will allow an increase in production capacity by more than 25%, as it will include innovative projects to support products under development and new production technologies. We have passionate and committed people who focus on safety, quality and reliability as we work to deliver medicines to patients around the world every day.”
The company currently has 1400 employees divided between the new headquarters in Milan, opened at the end of 2023, and the production plant in Borgo San Michele. The latter represents a key pillar of Johnson & Johnson’s global supply chain, producing more than 4 billion tablets per year for approximately 30 different products, 97% of which is exported, reaching patients around the world.
Mario Sturion, managing director of Johnson & Johnson Innovative Medicine Italia, highlighted the company’s commitment to the country: «Since 1975 we have been strongly rooted in Italy. With this extraordinary investment we strengthen our concrete commitment to favor and increase the attractiveness and competitiveness of the country, strengthening excellent pharmaceutical research and production. We trust that innovation will continue to be welcomed and adequately recognised, that the clinical trials ecosystem will improve and become faster and that the constructive dialogue between institutions and industry will continue and remain active.”
Marcello Cattani, president of Farmindustria, also highlighted the important growth of the pharmaceutical industry: «It is no coincidence that production has exceeded 50 billion euros, with exports of 49. Exports which in Latina reached 2 billion in the first quarter of 2024, an increase of 41% compared to 2023, consolidating the first position in the country. In Italy, pharmaceutical employment, especially among young people and women, continues to grow, reaching 70 thousand workers. Results are the result of investments, over 3.5 billion in total, which demonstrate the deep roots in the territory of companies with international and national capital”.
The Minister of Business and Made In Italy, Adolfo Urso, was very satisfied. «The pharmaceutical sector has become a new growth model for Made in Italy, thanks to the impressive investments in research and innovation – declared the minister yesterday at San Michele – This growth, 60% driven by foreign companies, allows the production fabric local involved in the supply chain to grow equally and promotes its internationalisation”.
The role of multinationals is crucial in promoting the development of small and medium-sized local businesses in the pharmaceutical supply chain, which grow in symbiosis with the giants of the sector.
«This is a sector that can give great satisfaction in opening Italy to the world and bringing the world to Italy – added the minister – Italy, following the European elections, has become the most reliable country at European level in capable of attracting more and more foreign investments”. The numbers confirm this positive trend. Today the Latina plant is an international center of attraction for qualified workers also coming from other countries with over 3,600 jobs supported in total between direct, indirect and induced employment.
«The pharmaceutical center of Lazio has a crucial role. – declared the President of the Region, Francesco Rocca – It is a sector that focuses on quality, as demonstrated by the level of personnel employed and the large investment in the research and development sectors. The objective for the future remains to further strengthen the pharmaceutical and biomedical sector and launch the Rome Technopole as a structural project, also thanks to the resources coming from the Pnrr, thus giving new life to the industrial sector and at the same time building concrete responses to the health needs of people in diagnostic and therapeutic fields”.
Senator Nicola Calandrini, president of the Budget Commission, highlighted that “being able to boast the presence of a company of this scale in the Lazio region is extremely important for our community”.
© ALL RIGHTS RESERVED
Read the full article at
The messenger
